CRDL Cardiol Therapeutics Inc.

-

Cardiol Therapeutics Beat Consensus Estimates

Wednesday, August 12, 2026 · 12:00 AM ET

Cardiol Therapeutics (CRDL) reported a loss of $0.04 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.09 per share. The company beat consensus estimates by 55.56%.

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.04)
Earnings Whisper®
Consensus Estimate
($0.09)
Earnings Surprise
Earnings Growth42.9 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth